If you have diabetes, your doctor might suggest Humalog (insulin lispro) as a treatment option for your condition. Along with other questions you may have about the drug, you could be wondering about ...

Humalog (insulin lispro) is a prescription drug that’s used to help treat diabetes. Humalog comes as a liquid solution for infusion or injection under the skin. Humalog comes in two versions: Humalog ...

Insulin lispro protamine suspension 75% (rDNA origin), insulin lispro 25% (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol. The primary activity of insulin is the regulation of glucose ...

INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Humalog ® 200 units/mL KwikPen ® (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a ...

Insulin lispro protamine suspension 50% (rDNA origin), insulin lispro 50% (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol. The primary activity of insulin including Humalog Mix50/50 is the ...

Humalog is given as an injection, and there are two types of the drug: Some forms of Humalog and Humalog Mix are available as generics or biosimilars. To learn more, see “Generic or biosimilar ...

New York, April 04, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Insulin Syringes Market Size, Share & Industry Trends Analysis Report By Disease, By Syringe ...

Humalog (insulin lispro) and Humulin N (insulin isophane human) are brand-name prescription* medications. They’re approved by the Food and Drug Administration (FDA) to help treat type 1 and type 2 ...

INDIANAPOLIS, Jan. 28, 2020 /PRNewswire/ -- Starting this month, Eli Lilly and Company (NYSE: LLY) will donate at least 200,000 KwikPens® to three relief organizations – Americares, Direct Relief and ...

Dublin, April 22, 2022 (GLOBE NEWSWIRE) -- The "Global Insulin Syringes Market Size, Share & Industry Trends Analysis Report By Disease (Type 2 Diabetes and Type 1 Diabetes), By Syringe Size, By End ...

LYON, France & INDIANAPOLIS--(BUSINESS WIRE)--Regulatory News: Adocia (Paris:ADOC) and Eli Lilly and Company (NYSE:LLY) announced today successful completion of an insulin pump study under the ...